JP2017533222A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533222A5 JP2017533222A5 JP2017523502A JP2017523502A JP2017533222A5 JP 2017533222 A5 JP2017533222 A5 JP 2017533222A5 JP 2017523502 A JP2017523502 A JP 2017523502A JP 2017523502 A JP2017523502 A JP 2017523502A JP 2017533222 A5 JP2017533222 A5 JP 2017533222A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- item
- pharmaceutical combination
- combination according
- brd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077042P | 2014-11-07 | 2014-11-07 | |
| US62/077,042 | 2014-11-07 | ||
| US201562150110P | 2015-04-20 | 2015-04-20 | |
| US62/150,110 | 2015-04-20 | ||
| PCT/US2015/059566 WO2016073913A1 (en) | 2014-11-07 | 2015-11-06 | Methods to target transcriptional control at super-enhancer regions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533222A JP2017533222A (ja) | 2017-11-09 |
| JP2017533222A5 true JP2017533222A5 (enExample) | 2018-12-20 |
| JP6689841B2 JP6689841B2 (ja) | 2020-04-28 |
Family
ID=55909897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523502A Expired - Fee Related JP6689841B2 (ja) | 2014-11-07 | 2015-11-06 | スーパーエンハンサー領域において転写制御を標的とする方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20180280407A1 (enExample) |
| EP (1) | EP3215135B1 (enExample) |
| JP (1) | JP6689841B2 (enExample) |
| KR (1) | KR20170092543A (enExample) |
| CN (1) | CN107205959B (enExample) |
| AU (1) | AU2015342813B2 (enExample) |
| BR (1) | BR112017009552A8 (enExample) |
| CA (1) | CA2965690A1 (enExample) |
| IL (1) | IL251816B (enExample) |
| MX (1) | MX385762B (enExample) |
| RU (1) | RU2737508C2 (enExample) |
| WO (1) | WO2016073913A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016252609B2 (en) | 2015-04-20 | 2022-06-30 | Sumitomo Pharma Oncology, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| HUE045585T2 (hu) | 2015-05-18 | 2020-01-28 | Tolero Pharmaceuticals Inc | Megnövelt biológiai hozzáférhetõséggel rendelkezõ Alvocidib gyógyszer-elõanyagok |
| AU2016301315C1 (en) | 2015-08-03 | 2022-07-07 | Sumitomo Pharma Oncology, Inc. | Combination therapies for treatment of cancer |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| CA3047557A1 (en) | 2016-12-19 | 2018-06-28 | Tolero Pharmaceuticals, Inc. | Profiling peptides and methods for sensitivity profiling |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| WO2019113260A1 (en) * | 2017-12-05 | 2019-06-13 | The Regents Of The University Of Colorado A Body Corporate | Genomic targets of histone deacetylase inhibitors (hdaci) and methods of use thereof |
| EP3758753A1 (en) * | 2018-02-27 | 2021-01-06 | Pfizer Inc | Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor |
| JP7654540B2 (ja) | 2018-10-15 | 2025-04-01 | マックスプランク－ゲセルシャフト・ツール・フェーデルング・デル・ヴィッセンシャフテン・エー・ファウ | 疾患の治療のための化合物およびこれをスクリーニングする方法 |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| EP3921650A1 (en) | 2019-02-08 | 2021-12-15 | Dewpoint Therapeutics, Inc. | Methods of characterizing condensate-associated characteristics of compounds and uses thereof |
| JP2022525149A (ja) | 2019-03-20 | 2022-05-11 | スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド | ベネトクラクスが失敗した急性骨髄性白血病（ａｍｌ）の処置 |
| KR20220084047A (ko) | 2019-09-18 | 2022-06-21 | 듀포인트 테라퓨틱스, 인크. | 응축물 관련 특이성에 대한 스크리닝 방법 및 이의 용도 |
| EP4453261A1 (en) * | 2021-12-22 | 2024-10-30 | Cornell University | Prognostic/predictive epigenetic breast cancer signature |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20030026069A (ko) * | 2001-09-24 | 2003-03-31 | 주식회사 엘지생명과학 | 티엔에프계 단백질과 플라보피리돌의 조합에 의한 암세포특이적인 세포사멸 유도용 조성물 |
| RU2438664C2 (ru) * | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
| EP2561867A1 (en) * | 2011-08-22 | 2013-02-27 | Lead Discovery Center GmbH | CDK9 inhibitors in the treatment of midline carcinoma |
| US11446309B2 (en) * | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
| US10300073B2 (en) * | 2014-10-14 | 2019-05-28 | The Regents Of The University Of California | Use of CDK9 and BRD4 inhibitors to inhibit inflammation |
-
2015
- 2015-11-06 MX MX2017005861A patent/MX385762B/es unknown
- 2015-11-06 KR KR1020177013707A patent/KR20170092543A/ko not_active Ceased
- 2015-11-06 EP EP15857385.7A patent/EP3215135B1/en active Active
- 2015-11-06 JP JP2017523502A patent/JP6689841B2/ja not_active Expired - Fee Related
- 2015-11-06 CA CA2965690A patent/CA2965690A1/en not_active Abandoned
- 2015-11-06 RU RU2017118833A patent/RU2737508C2/ru active
- 2015-11-06 US US15/524,953 patent/US20180280407A1/en not_active Abandoned
- 2015-11-06 WO PCT/US2015/059566 patent/WO2016073913A1/en not_active Ceased
- 2015-11-06 AU AU2015342813A patent/AU2015342813B2/en not_active Ceased
- 2015-11-06 CN CN201580060262.XA patent/CN107205959B/zh not_active Expired - Fee Related
- 2015-11-06 BR BR112017009552A patent/BR112017009552A8/pt not_active Application Discontinuation
-
2017
- 2017-04-20 IL IL251816A patent/IL251816B/en unknown
-
2019
- 2019-12-30 US US16/730,810 patent/US20200316084A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017118833A (ru) | Способы воздействия на транскрипционный контроль в суперэнхансерных областях | |
| CY1121735T1 (el) | 7-benzyλ-10-(2-meθyλobenzyλ)-2,6,7,8,9,10-eξaϋδpoϊmiδazo[1,2-α]πυριδο[4,3-d]πυριμιδιν-5(3η)-ονη για χρηση στην αγωγη του καρκινου | |
| Kuryk et al. | Synergistic anti‐tumor efficacy of immunogenic adenovirus ONCOS‐102 (Ad5/3‐D24‐GM‐CSF) and standard of care chemotherapy in preclinical mesothelioma model | |
| MX2024010140A (es) | Nuevos metodos. | |
| CY1122064T1 (el) | Σκευασματα 4-αμινο-2- (2,6-διοξοπιπεριδιν-3-υλο)ισοϊνδολινο-1,3-διονης | |
| RU2017143776A (ru) | Пролекарства альвоцидиба, имеющие повышенную биодоступность | |
| JP2018522038A5 (enExample) | ||
| CL2018002807A1 (es) | Métodos de tratamiento de cánceres pediátricos. | |
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| MX2021004639A (es) | Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos. | |
| EA200801671A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| RU2012147739A (ru) | Пероральные составы, содержащие аналоги цитидина, и способы их использования | |
| SG10201902664RA (en) | Combination therapy for treating cancer | |
| AR029084A1 (es) | Composiciones y metodos para el tratamiento del cancer | |
| EA200900912A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| CY1121628T1 (el) | 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης | |
| FI3362065T3 (fi) | Ivosidenibiä, sytarabiinia ja daunorubisiinia tai idarubisiinia käsittävä yhdistelmähoito akuutin myelooisen leukemian hoitamiseksi | |
| RU2018106886A (ru) | Комбинированные терапии для лечения рака | |
| AR075179A1 (es) | Formulaciones galenicas de compuestos organicos que comprenden alisquireno | |
| CU20090007A6 (es) | Un compuesto farmacéutico y un proceso del mismo | |
| JP2019506392A5 (enExample) | ||
| Zhang | Problematic analysis and inadequate toxicity data in phase III apatinib trial in gastric cancer | |
| Lin et al. | Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo | |
| MX2019005104A (es) | Composiciones de zinc-y-pga y métodos para tratar el cancer. | |
| JP2021514975A5 (enExample) |